Arca
Skip to content
Tools
Tools

Back pain

Drug research and approvals for back pain: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 434 studies of back pain are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.

  • Recruiting worldwide: 434
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 434 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 10

Phase 3 12 of 21

Phase 2 10

Phase 1 or earlier 2

How its trials ended

2,498 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 417 whose ending is known, 52% met their primary endpoint, 8% missed it and 40% stopped early.

  • Completed, result not reported1,25550%
  • Ongoing45518%
  • Status unknown37115%
  • Met its primary endpoint2159%
  • Stopped: other or unclear914%
  • Stopped: enrollment or feasibility432%
  • Missed its primary endpoint351%
  • Stopped: sponsor or business decision151%
  • Stopped: funding12<1%
  • Stopped: lack of efficacy5<1%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Aug 27, 2021Hindering the synaptic reconsolidation with the help of propranolol: a feasibility study of a novel approach for the treatment of chronic painPropranololUniversité De SherbrookeClosed
Feb 5, 2018A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of fasinumab in patients with moderate-to-severe chronic low…REGN475 (fasinumab)RegeneronOngoing
Jan 8, 2016A randomized, double-blind, multi-dose, placebo-controlled phase 2/3 study to evaluate the efficacy and safety of fasinumab in patients with moderate to severe…REGN475 (fasinumab / Sar 164877)RegeneronOngoing
Oct 29, 2015Genetic variants associated with the occurrence of localized low back pain or low back pain with widespread pain symptoms, and their response to treatment with…PropranololMcGill UniversityOngoing
Jul 23, 2015A phase 3, randomized, double-blind, placebo and active-controlled, multicenter, parallel-group study of the analgesic efficacy and safety of tanezumab in…PF-04383119 (tanezumab)PfizerClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.